Blood-based transcriptomic biomarkers for response to [¹⁷⁷Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors.

ABSTRACT:

Background

[¹⁷⁷Lu]Lu-DOTA-TATE is an effective treatment for metastatic neuroendocrine tumors (NETs) expressing somatostatin receptors. While the tumor uptake [¹⁷⁷Lu]Lu-DOTA-TATE of has shown potential as a predictive biomarker, patient response to the treatment varies significantly. In this study, we aim to identify a predictive blood-based transcriptomic biomarker to better understand individual responses to [¹⁷⁷Lu]Lu-DOTA-TATE therapy.

Results

Twenty-six patients were prospectively enrolled in this study. Responders were defined as patients who showed partial response or stable disease and non-responders were defined as patients who showed progressive disease according to RECIST1.1 criteria. Of the 26 patients, responders (n = 20) exhibite

SUBMITTER: Sung H 

PROVIDER: S-EPMC12317932 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature